Science magazine and the watchdog Retraction Watch jointly published investigations on July 23 detailing the death of a six-year-old Chinese girl following an experimental gene-editing treatment. The reports have reignited concerns over research ethics, informed consent, and regulatory oversight in China’s rapidly advancing biotechnology sector.
According to the investigations, the girl became the world’s first known patient to receive an in vivo base-editing therapy targeting the brain. Researchers at Shanghai Xinhua Hospital injected trillions of viral vectors carrying a customized gene-editing system into her cerebrospinal fluid to treat a rare genetic disorder. Her family reportedly paid US$860,000 to help fund development of the experimental therapy. The child developed a fever and signs of kidney injury after treatment and died one week later. Hospital investigators concluded that the most likely cause of death was an immune reaction to the viral delivery vector.
The investigations further report that both the girl’s death and her family’s financial support for the research were omitted from a Nature paper published by the research team in February 2026. According to Science, seven international experts in gene therapy and bioethics questioned whether the parents had been fully informed of the treatment’s risks and whether the trial should have proceeded given its highly uncertain prospects. The reports also raise questions about the validity of the published animal data and whether Nature should correct or reconsider the paper.
The case has intensified scrutiny of research integrity and medical ethics in China. Although the hospital reportedly received an administrative penalty, no public disciplinary action has been announced against the lead researcher, renewing questions about accountability and oversight in China’s biomedical research system. Source: Epoch Times, July 26, 2026
https://www.epochtimes.com/gb/26/7/25/n14817406.htm